VEGFA and glioblastoma: Before the introduction of bevacizumab, concurrent vincristine and carboplatin use was associated with exceptional treatment results in glioblastoma.[23,26] Vincristine, a microtubule-destabilizing drug that exhibits antiangiogenic and antitumoral activity, was shown to affect VEGF expression in glioblastoma cells.[22] Conversely, carboplatin kills tumor cells by interfering with deoxyribonucleic acid (DNA) duplication[37,38] and is usually used in patients with worst disease status due to its severe toxicity characteristics.